Neuracle eyes Shanghai IPO as global BCI funding surges

Summary

BioWorld reported that Neuracle Medical Technology is pursuing a Shanghai STAR Market IPO that could make it China’s first publicly listed invasive BCI company, months after winning approval for the country’s first invasive brain-computer interface system. The coverage places Neuracle within a broader wave of rising global BCI investment, positioning the listing as a key valuation benchmark for future neurotech financings.